Lipid Lowering Drugs Summary

 

SUMMARY 👉 

Bempedoic Acid 

Class

ATP-citrate lyase inhibitor

Mechanism of Action

Bempedoic acid inhibits hepatic cholesterol synthesis upstream of statins, leading to reduced LDL-cholesterol (LDL-C).

The drug is activated only in the liver, not in skeletal muscle.

Importance of Bempedoic Acid 

Both patients with Type 2 Diabetes and non-diabetic patients with ASCVD or very high cardiovascular risk share the same therapeutic goal:

👉 Aggressive LDL-C reduction to lower cardiovascular events

While statins remain first-line therapy, real-world challenges include:

 • True statin intolerance

 • Failure to achieve LDL targets despite maximally tolerated statins ± ezetimibe

For these patients, bempedoic acid provides an effective non-statin option.

Indications (Applies to Both Diabetic & Non-Diabetic Patients)

Bempedoic acid should be considered in patients who:

✔️ Have established ASCVD

✔️ OR have very high ASCVD risk

✔️ AND either:

 • True statin intolerance, or

 • Inadequate LDL-C lowering despite:

 • Maximally tolerated statin

 • ± ezetimibe

Diabetes is not required for use.

ADA emphasizes it because diabetes confers high CV risk, but the indication is risk-based, not diabetes-specific.

Position in Lipid-Lowering Algorithm (Universal)

Stepwise LDL-C Management (Diabetic & Non-Diabetic):

1️⃣ Moderate- or high-intensity statin

2️⃣ Add ezetimibe if LDL-C goal not achieved

3️⃣ Add PCSK9 inhibitor or bempedoic acid if:

 • Statin intolerance

 • Inadequate LDL-C reduction

 • Cost or access limitations

 • Preference for oral therapy

Bempedoic acid may be used as an add-on or alternative, not first-line.

Evidence Supporting Use

CLEAR Outcomes Trial

 • Included patients with and without diabetes

 • Demonstrated:

 • ~15–25% LDL-C reduction

 • Significant reduction in major adverse cardiovascular events

• Benefit observed independent of diabetes status

• Particularly effective in statin-intolerant patients

Adverse Effects & Exam-Relevant Cautions

 • ↑ Uric acid → gout risk

 • Rare tendon rupture

 • Mild ↑ liver enzymes

 • Avoid in severe liver disease

 • Not recommended in pregnancy

🔹 No muscle toxicity, unlike statins

Lipid Lowering Drugs – Concise Clinical Summary

Overview

Lipid lowering drugs are used to reduce atherosclerotic cardiovascular disease (ASCVD) risk by lowering LDL-cholesterol, triglycerides, or increasing HDL-cholesterol. LDL-C reduction is the primary target in most guidelines.

1. Statins (HMG-CoA Reductase Inhibitors)

Examples: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin

Mechanism

Inhibit HMG-CoA reductase → ↓ hepatic cholesterol synthesis → ↑ LDL receptor expression → ↓ LDL-C

Lipid Effect

LDL-C ↓ 30–60% (dose dependent)

Triglycerides ↓ 10–30%

HDL-C ↑ 5–10%

Clinical Benefits

Strongest evidence for reducing MI, stroke, and CV mortality

First-line therapy in primary and secondary prevention

Adverse Effects

Myalgia, myopathy, rare rhabdomyolysis

Mild transaminase elevation

Small increase in diabetes risk (benefit outweighs risk)

2. Ezetimibe

Mechanism

Inhibits intestinal cholesterol absorption via NPC1L1 transporter

Lipid Effect

LDL-C ↓ 15–25%

Minimal effect on TG and HDL

Clinical Use

Add-on to statin when LDL target not achieved

Alternative in statin intolerance

Evidence

IMPROVE-IT trial showed additional CV risk reduction when added to statin

3. PCSK9 Inhibitors

Examples: Evolocumab, Alirocumab

Mechanism

Inhibit PCSK9 → prevent LDL receptor degradation → ↑ LDL clearance

Lipid Effect

LDL-C ↓ 50–60%

Clinical Use

Very high-risk ASCVD

Familial hypercholesterolemia

Statin intolerance or inadequate response

Evidence

FOURIER, ODYSSEY trials showed significant CV event reduction

Limitations

High cost

Subcutaneous injection

4. Bempedoic Acid

Mechanism

Inhibits ATP-citrate lyase (upstream of HMG-CoA reductase)

Lipid Effect

LDL-C ↓ 15–20%

Clinical Use

Statin-intolerant patients

Can be combined with ezetimibe

Adverse Effects

Hyperuricemia, gout

Tendon rupture (rare)

5. Fibrates

Examples: Fenofibrate, Gemfibrozil

Mechanism

PPAR-α activation → ↑ lipoprotein lipase activity

Lipid Effect

Triglycerides ↓ 30–50%

HDL-C ↑ 10–20%

LDL variable

Clinical Use

Severe hypertriglyceridemia (TG > 500 mg/dL) to prevent pancreatitis

Adverse Effects

Myopathy risk (higher with statins, especially gemfibrozil)

Gallstones

6. Omega-3 Fatty Acids

Examples: Icosapent ethyl (EPA), fish oil

Mechanism

Reduce hepatic VLDL synthesis

Lipid Effect

Triglycerides ↓ 20–40%

Clinical Use

Hypertriglyceridemia

Icosapent ethyl in high-risk patients with elevated TG on statins

Evidence

REDUCE-IT trial showed CV event reduction with pure EPA

7. Niacin (Vitamin B3)

Mechanism

↓ Hepatic VLDL synthesis

Lipid Effect

LDL ↓

TG ↓

HDL ↑ significantly

Current Status

Not routinely recommended

No additional CV benefit when added to statins

Adverse Effects

Flushing

Hyperglycemia

Hepatotoxicity

8. Bile Acid Sequestrants

Examples: Cholestyramine, Colesevelam

Mechanism

Bind bile acids in gut → ↑ conversion of cholesterol to bile acids

Lipid Effect

LDL-C ↓ 15–25%

TG may increase

Limitations

GI intolerance

Drug interactions

Guideline-Based Approach

High-intensity statin for ASCVD or very high risk

Add ezetimibe if LDL target not achieved

Add PCSK9 inhibitor if still above goal

Treat triglycerides primarily when ≥500 mg/dL

Key Takeaway

Statins remain the cornerstone of lipid management. Non-statin therapies are selected based on residual LDL risk, triglyceride level, intolerance, and overall ASCVD risk profile.

Thanks